Undiagnosed diabetes affects approximately 500,000 people in Sweden, particularly across regions like Sörmland, Skåne, and Kalmar. This systemic public health gap increases the risk of irreversible organ damage. Early detection through targeted screening is critical to prevent long-term complications such as chronic kidney disease, retinopathy, and cardiovascular events.
The current crisis in the Swedish healthcare landscape is not a failure of medication, but a failure of detection. When Type 2 Diabetes (T2D) remains undiagnosed, the body exists in a state of chronic hyperglycemia—excessive blood glucose—which acts as a slow-acting toxin to the vascular system. By the time a patient presents with classic symptoms, the window for primary prevention has often closed, leaving clinicians to manage damage rather than prevent it.
In Plain English: The Clinical Takeaway
- The Silent Window: You can have diabetes for years without feeling “sick” because the body adapts to high sugar levels until a tipping point is reached.
- The Gold Standard Test: An HbA1c test measures your average blood sugar over three months, providing a more accurate picture than a single finger-prick test.
- Prevention is Possible: Detecting “prediabetes” allows for lifestyle interventions that can actually reverse the progression toward full-blown diabetes.
The Metabolic Stealth: Why Diabetes Remains Undiagnosed
The primary challenge in identifying the estimated 500,000 undiagnosed Swedes lies in the mechanism of action of insulin resistance. In Type 2 Diabetes, the body’s cells become less responsive to insulin—the hormone responsible for ushering glucose from the bloodstream into the cells for energy. To compensate, the pancreas overproduces insulin (hyperinsulinemia) to maintain normal glucose levels.
This compensatory phase can last for years. During this time, the patient is technically prediabetic or early-stage diabetic, but their fasting glucose may still appear within a “near-normal” range. However, the internal physiological stress is significant. The chronic elevation of glucose leads to the formation of Advanced Glycation End-products (AGEs), which damage the endothelial lining of blood vessels.
Clinically, we rely on the HbA1c test (glycated hemoglobin). This test measures the percentage of hemoglobin proteins that have glucose attached to them. Because red blood cells live for about 120 days, this provides a weighted average of blood glucose over the preceding three months, bypassing the volatility of daily fluctuations. When screening is neglected at the primary care level, these biomarkers remain unmonitored, allowing the disease to progress silently.
Regional Disparities and the European Healthcare Bridge
The urgency voiced in Sörmland, Skåne, and Kalmar highlights a fragmentation in regional healthcare delivery. While Sweden adheres to general guidelines aligned with the European Medicines Agency (EMA) and the World Health Organization (WHO), the implementation of screening protocols varies by region. The gap is often found in the transition from opportunistic screening (testing when a patient visits for something else) to systematic screening (targeting high-risk populations regardless of symptoms).
On a broader scale, the World Health Organization emphasizes that early diagnosis is the only way to reduce the global burden of non-communicable diseases. In the US, the CDC utilizes a rigorous risk-assessment tool to trigger screening, a model that could mitigate the “missing millions” seen in the Swedish regional reports. The failure to identify these patients leads to an increased reliance on high-cost tertiary care—such as dialysis and amputation surgeries—which places a far greater strain on the public health budget than early primary care screening would.
“The global prevalence of diabetes is rising, but the most dangerous trend is the proportion of people living with the condition who are unaware of it. Undiagnosed diabetes is a catalyst for premature cardiovascular death.” — Representative guidance from the International Diabetes Federation (IDF) on global screening initiatives.
The Physiological Toll: Microvascular vs. Macrovascular Decay
When diabetes remains undetected, the damage occurs across two primary pathways. Microvascular complications affect the smallest blood vessels, leading to diabetic retinopathy (blindness), nephropathy (kidney failure), and neuropathy (nerve damage, often starting in the feet). Macrovascular complications involve larger arteries, significantly increasing the probability of myocardial infarction (heart attack) and stroke.
The relationship between hyperglycemia and vascular decay is linear: the longer the blood glucose remains elevated, the higher the probability of systemic failure. Research published in The Lancet underscores that intensive glucose control initiated early in the disease course significantly reduces the risk of these endpoints compared to delayed intervention.
The underlying research supporting these screening drives is typically funded by non-profit health organizations and national health registries, such as the Swedish National Diabetes Register (NDR). This ensures that the push for screening is based on population health outcomes rather than pharmaceutical profit motives.
Diagnostic Thresholds for Diabetes Screening
| Category | HbA1c Level (%) | Fasting Plasma Glucose (mg/dL) | Clinical Status |
|---|---|---|---|
| Normal | Below 5.7% | 70–99 | Healthy metabolic function. |
| Prediabetes | 5.7% to 6.4% | 100–125 | High risk; reversible with intervention. |
| Diabetes | 6.5% or higher | 126 or higher | Chronic hyperglycemia; requires management. |
Contraindications & When to Consult a Doctor
While screening is generally safe and non-invasive, patients should be aware of specific contexts. For those with certain hemoglobinopathies (blood disorders that affect hemoglobin shape), the HbA1c test may provide an inaccurate reading. In these cases, a fructosamine test or continuous glucose monitoring (CGM) may be required.
Consult a physician immediately if you experience the following “red flag” symptoms:
- Polyuria & Polydipsia: Excessive urination and unquenchable thirst.
- Unexplained Weight Loss: Rapid loss of muscle mass despite normal eating habits.
- Blurred Vision: Sudden changes in vision caused by glucose-induced swelling of the lens.
- Slow-Healing Wounds: Cuts or bruises that seize weeks to heal, indicating poor peripheral circulation.
- Paresthesia: Tingling or numbness in the hands and feet (diabetic neuropathy).
The Path Forward: From Debate to Diagnosis
The debate echoing through the regional press in Sweden is a wake-up call for a shift toward proactive metabolic surveillance. We must move away from a reactive medical model—where we wait for the patient to become symptomatic—and toward a predictive model. By integrating HbA1c screening into routine annual check-ups for adults over 40, or younger adults with a BMI over 25, the “missing 500,000” can be identified, and treated.
The trajectory of diabetes management is moving toward precision medicine, but precision is useless without detection. The goal is not merely to manage a disease, but to intercept it in the prediabetic phase, utilizing evidence-based lifestyle modifications and pharmacological support to preserve organ function for decades to come.
